Eribulin mesylate has demonstrated clinical benefit as a first-line therapy for locally recurrent or metastatic HER2- negative breast cancer, according to results of a phase II, multicenter, single-arm study.
Eribulin mesylate has demonstrated clinical benefit as a first-line therapy for locally recurrent or metastatic HER2- negative breast cancer, according to results of a phase II, multicenter, single-arm study.
“Eribulin has been approved by the FDA in late-line metastatic breast cancer, and it showed an overall survival benefit in patients who had taken previous anthracyclines and taxanes who had equal or more than two cycles of previous chemotherapy,” said Kristi McIntyre, MD, principal investigator of the study, at the San Antonio Breast Cancer Symposium in December 2013.
“We wanted to move it to first line and see, in the initial phase II study, its efficacy and safety profile. The overall response rate was quite favorable at 29%, but the clinical benefit rate, which was CR, PR and stable disease, was 52%, which is quite favorable,” said McIntyre, a medical oncologist and hematologist with Texas Oncology, Dallas, Texas.
Patients with ≥12 months since prior neoadjuvant or adjuvant chemotherapy received eribulin mesylate 1.4 mg/ m2 IV on days 1 and 8 of each 3-week cycle. The primary endpoint was objective response rate (ORR), and secondary endpoints included safety, progression-free survival (PFS), time to response (TTR), and duration of response (DOR). Tumor assessments were conducted every 6 weeks for the first 6 cycles and every 6 to 12 weeks thereafter per RECIST 1.1.
Fifty-six patients enrolled and received eribulin. Thirty-two patients (57%) completed at least 6 cycles of treatment; among the 24 patients who completed fewer than 6 cycles, reasons for not completing were progressive disease (PD; n=18), adverse events (AEs; n=3), and patient choice (n=3).
Stable disease (SD) rate was 48%. Median PFS was 6.8 months. Thirty-five patients (63%) had grade 3/4 treatment-related AEs. Treatment-related serious AEs occurred in five patients (9%): neutropenia (5%), febrile neutropenia (5%), and leukopenia (2%).
“Eribulin is a non-taxane, but it also targets the microtubule as a taxane would. Clinically, being a non-taxane is important because you don’t have hypersensitivity reactions and the requirement for premedications, etc. It is very convenient to give. Its convenience really helps patient stick with it,” McIntyre said.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More
UGT1A1 Status Underutilized in Predicting Sacituzumab Toxicity in MBC
April 8th 2024During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the value of testing for UGT1A1 status in patients receiving sacituzumab govitecan for hormone receptor–positive breast cancer in the second article of a 2-part series.
Read More